Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) had its price target upped by Maxim Group from $17.00 to $19.00 in a report issued on Tuesday. Maxim Group currently has a buy rating on the biopharmaceutical company’s stock.

Other equities research analysts have also recently issued research reports about the stock. Zacks Investment Research raised shares of Sucampo Pharmaceuticals from a sell rating to a hold rating in a research note on Monday, August 8th. Jefferies Group lowered their price target on shares of Sucampo Pharmaceuticals from $16.00 to $14.00 and set a hold rating on the stock in a research report on Thursday, August 4th. Mizuho cut shares of Sucampo Pharmaceuticals from a buy rating to a neutral rating and set a $13.00 price target on the stock. in a research report on Thursday, August 4th. Vetr cut shares of Sucampo Pharmaceuticals from a strong-buy rating to a buy rating and set a $14.00 price target on the stock. in a research report on Monday, September 19th. Finally, Northland Securities assumed coverage on shares of Sucampo Pharmaceuticals in a research report on Wednesday, September 7th. They set an outperform rating and a $15.00 price target on the stock. Five analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus target price of $17.33.

Sucampo Pharmaceuticals (NASDAQ:SCMP) traded down 1.735% on Tuesday, reaching $15.575. 193,951 shares of the company traded hands. Sucampo Pharmaceuticals has a 1-year low of $9.59 and a 1-year high of $18.75. The stock has a market capitalization of $666.89 million, a price-to-earnings ratio of 52.618 and a beta of 1.62. The stock has a 50 day moving average of $12.79 and a 200-day moving average of $11.84.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last announced its earnings results on Wednesday, November 9th. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.26 by $0.02. Sucampo Pharmaceuticals had a net margin of 6.29% and a return on equity of 44.19%. The company had revenue of $57.90 million for the quarter, compared to analysts’ expectations of $51.30 million. During the same quarter in the previous year, the company posted $0.16 EPS. The firm’s quarterly revenue was up 73.4% on a year-over-year basis. On average, equities analysts anticipate that Sucampo Pharmaceuticals will post $1.22 EPS for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of SCMP. Globeflex Capital L P increased its position in Sucampo Pharmaceuticals by 0.3% in the second quarter. Globeflex Capital L P now owns 23,649 shares of the biopharmaceutical company’s stock worth $259,000 after buying an additional 61 shares during the period. Smith Asset Management Group LP increased its position in Sucampo Pharmaceuticals by 2.1% in the third quarter. Smith Asset Management Group LP now owns 10,950 shares of the biopharmaceutical company’s stock worth $135,000 after buying an additional 220 shares during the period. ProShare Advisors LLC increased its position in Sucampo Pharmaceuticals by 1.0% in the second quarter. ProShare Advisors LLC now owns 36,954 shares of the biopharmaceutical company’s stock worth $405,000 after buying an additional 369 shares during the period. BlackRock Group LTD increased its position in Sucampo Pharmaceuticals by 2.0% in the third quarter. BlackRock Group LTD now owns 20,706 shares of the biopharmaceutical company’s stock worth $255,000 after buying an additional 405 shares during the period. Finally, Rhumbline Advisers increased its position in Sucampo Pharmaceuticals by 1.6% in the third quarter. Rhumbline Advisers now owns 27,355 shares of the biopharmaceutical company’s stock worth $337,000 after buying an additional 425 shares during the period. Institutional investors and hedge funds own 41.14% of the company’s stock.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It operates through development and commercialization of pharmaceutical products segment. Its operations are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts operations in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, the United Kingdom.

5 Day Chart for NASDAQ:SCMP

Receive News & Stock Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.